- Home
- LZ vs PHAT Comparison
LZ vs PHAT Comparison
Compare LZ & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LZ | PHAT |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 894.0M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LZ | PHAT |
|---|---|---|
| Price | $5.49 | $10.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $9.79 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 2.2M | 940.4K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $756,043,000.00 | $175,110,000.00 |
| Revenue This Year | $11.50 | $92.15 |
| Revenue Next Year | $7.11 | $59.79 |
| P/E Ratio | $72.44 | ★ N/A |
| Revenue Growth | 10.88 | ★ 216.93 |
| 52 Week Low | $5.77 | $2.21 |
| 52 Week High | $12.40 | $18.31 |
Technical Indicators
Market Signals| Indicator | LZ | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 25.26 | 43.50 |
| Support Level | N/A | $10.06 |
| Resistance Level | $7.23 | $12.62 |
| Average True Range (ATR) | 0.27 | 0.67 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 0.50 | 35.00 |
Price Performance
Historical ComparisonAbout LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.